DOI: 10.1055/s-00050348

Indian Journal of Medical and Paediatric Oncology

References

James ND, Sydes MR, Clarke NW. et al
Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial.

Lancet 2016;
387 (10024) 1163-1177

Download Bibliographical Data

Access:
Access: